Impact of SSTR PET on Inter-Observer Variability of Target Delineation of Meningioma and the Possibility of Using Threshold-Based Segmentations in Radiation Oncology.

Inter-observer variability PET/CT meningioma imaging radiation therapy planning somatostatin receptor PET

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
13 Sep 2022
Historique:
received: 10 05 2022
revised: 31 08 2022
accepted: 08 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

Aim: The aim of this study was to assess the effects of including somatostatin receptor agonist (SSTR) PET imaging in meningioma radiotherapy planning by means of changes in inter-observer variability (IOV). Further, the possibility of using threshold-based delineation approaches for semiautomatic tumor volume definition was assessed. Patients and Methods: Sixteen patients with meningioma undergoing fractionated radiotherapy were delineated by five radiation oncologists. IOV was calculated by comparing each delineation to a consensus delineation, based on the simultaneous truth and performance level estimation (STAPLE) algorithm. The consensus delineation was used to adapt a threshold-based delineation, based on a maximization of the mean Dice coefficient. To test the threshold-based approach, seven patients with SSTR-positive meningioma were additionally evaluated as a validation group. Results: The average Dice coefficients for delineations based on MRI alone was 0.84 ± 0.12. For delineation based on MRI + PET, a significantly higher dice coefficient of 0.87 ± 0.08 was found (p < 0.001). The Hausdorff distance decreased from 10.96 ± 11.98 mm to 8.83 ± 12.21 mm (p < 0.001) when adding PET for the lesion delineation. The best threshold value for a threshold-based delineation was found to be 14.0% of the SUVmax, with an average Dice coefficient of 0.50 ± 0.19 compared to the consensus delineation. In the validation cohort, a Dice coefficient of 0.56 ± 0.29 and a Hausdorff coefficient of 27.15 ± 21.54 mm were found for the threshold-based approach. Conclusions: SSTR-PET added to standard imaging with CT and MRI reduces the IOV in radiotherapy planning for patients with meningioma. When using a threshold-based approach for PET-based delineation of meningioma, a relatively low threshold of 14.0% of the SUVmax was found to provide the best agreement with a consensus delineation.

Identifiants

pubmed: 36139596
pii: cancers14184435
doi: 10.3390/cancers14184435
pmc: PMC9497299
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
IEEE Trans Med Imaging. 2004 Jul;23(7):903-21
pubmed: 15250643
J Med Imaging Radiat Oncol. 2016 Jun;60(3):393-406
pubmed: 27170216
J Nucl Med. 2017 Oct;58(10):1580-1587
pubmed: 28450556
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):222-7
pubmed: 16488553
PLoS One. 2018 Apr 13;13(4):e0195798
pubmed: 29652908
Acta Neuropathol. 2015 Sep;130(3):441-3
pubmed: 26195322
Clin Oncol (R Coll Radiol). 2017 Jul;29(7):448-458
pubmed: 28433399
Eur J Nucl Med Mol Imaging. 2016 May;43(5):911-924
pubmed: 26567163
Int J Cancer. 1998 May 29;76(5):620-7
pubmed: 9610716
Radiat Oncol. 2018 Nov 12;13(1):219
pubmed: 30419929
Nuklearmedizin. 2013;52(1):28-35
pubmed: 23348719
Int J Mol Imaging. 2013;2013:980769
pubmed: 23533750
Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1409-15
pubmed: 22669255
Cancers (Basel). 2021 Sep 20;13(18):
pubmed: 34572933
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):310-8
pubmed: 19763565
J Nucl Med. 2001 Jul;42(7):1053-6
pubmed: 11438627
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
J Nucl Med. 2015 Mar;56(3):347-53
pubmed: 25635133
Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):859-865
pubmed: 35460804
Radiat Oncol. 2009 Nov 18;4:56
pubmed: 19922642
EJNMMI Phys. 2021 Feb 27;8(1):21
pubmed: 33638729

Auteurs

Florian Kriwanek (F)

Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria.

Leo Ulbrich (L)

Department of Radiation Oncology, Medical University of Vienna, 1090 Vienna, Austria.

Wolfgang Lechner (W)

Department of Radiation Oncology, Medical University of Vienna, 1090 Vienna, Austria.

Carola Lütgendorf-Caucig (C)

MedAustron Ion Therapy Center, 2700 Wiener Neustadt, Austria.

Stefan Konrad (S)

Department of Radiation Oncology, Medical University of Vienna, 1090 Vienna, Austria.

Cora Waldstein (C)

Department of Radiation Oncology, Medical University of Vienna, 1090 Vienna, Austria.

Harald Herrmann (H)

Department of Radiation Oncology, Medical University of Vienna, 1090 Vienna, Austria.

Dietmar Georg (D)

Department of Radiation Oncology, Medical University of Vienna, 1090 Vienna, Austria.

Joachim Widder (J)

Department of Radiation Oncology, Medical University of Vienna, 1090 Vienna, Austria.

Tatjana Traub-Weidinger (T)

Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria.

Ivo Rausch (I)

QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, 1090 Vienna, Austria.

Classifications MeSH